Antiangiogenic Activity of Sterically Stabilized Liposomes Containing Paclitaxel (SSL-PTX): In Vitro and In Vivo

Huang, Yue; Chen, Xiaomei; Zhao, Bing-Xiang; Ke, Xiyu; Zhao, Bojun; Zhao, Xin; Wang, Ying; Zhang, Xuan; Qiang, Zhang

doi:10.1208/s12249-010-9430-z

Cited by 22 publications

(12 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The effect of NGR-SSL-CA4 on U87-MG cell proliferation was analyzed by SRB assay as described previously [20]. As shown in Figure 2B, anti-proliferative activity of CA4 in all CA4 formulations was observed in U87-MG cells.…”

Section: Resultsmentioning

confidence: 83%

Multi-targeting NGR-modified liposomes recognizing glioma tumor cells and vasculogenic mimicry for improving anti-glioma therapy

et al. 2016

Self Cite

View full text Add to dashboard Cite

Like the anti-angiogenic strategy, anti-vascular mimicry is considered as a novel targeting strategy for glioma. In the present study, we used NGR as a targeting ligand and prepared NGR-modified liposomes containing combretastatin A4 (NGR-SSL-CA4) in order to evaluate their potential targeting of glioma tumor cells and vasculogenic mimicry (VM) formed by glioma cells as well as their anti-VM activity in mice with glioma tumor cells. NGR-SSL-CA4 was prepared by a thin-film hydration method. The in vitro targeting of U87-MG (human glioma tumor cells) by NGR-modified liposomes was evaluated. The in vivo targeting activity of NGR-modified liposomes was tested in U87-MG orthotopic tumor-bearing nude mice. The anti-VM activity of NGR-SSL-CA4 was also investigated in vitro and in vivo. The targeting activity of the NGR-modified liposomes was demonstrated by in vitro flow cytometry and in vivo biodistribution. The in vitro anti-VM activity of NGR-SSL-CA4 was indicated in a series of cell migration and VM channel experiments. NGR-SSL-CA4 produced very marked anti-tumor and anti-VM activity in U87-MG orthotopic tumor-bearing mice in vivo. Overall, the NGR-SSL-CA4 has great potential in the multi-targeting therapy of glioma involving U87-MG cells, and the VM formed by U87-MG cells as well as endothelial cells producing anti-U87-MG cells, and anti-VM formed by U87-MG cells as well as anti-endothelial cell activity.

show abstract

Section: Resultsmentioning

confidence: 83%

Multi-targeting NGR-modified liposomes recognizing glioma tumor cells and vasculogenic mimicry for improving anti-glioma therapy

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

“…The metronomic application of pegylated PTX liposomes was the most efficient in anti-angiogenic activity as determined by microvessel density assessment. These results indicate that frequent administration of pegylated PTX liposomes had an anti-angiogenic effect that blocked the blood supply and may be more effective in suppressing tumor growth in vivo [56].…”

Section: Application Of Pegylated Paclitaxel-containing Liposomes In mentioning

confidence: 75%

Liposomal paclitaxel formulations

Koudelka

Tuřánek

2012

Journal of Controlled Release

298

247

View full text Add to dashboard Cite

“…The effect of DCA on C6 cell proliferation was analyzed with the SRB assay 31,32. Briefly, C6 cells were plated in 96-well culture plates (1 × 10 4 cells/well).…”

Section: Methodsmentioning

confidence: 99%

Antitumor activity of dichloroacetate on C6 glioma cell: in vitro and in vivo evaluation

Yu¹,

Zhao²,

Ren³

et al. 2013

OTT

Self Cite

View full text Add to dashboard Cite

Dichloroacetate (DCA), a small molecule mitochondria-targeting agent, can penetrate the blood–brain barrier, showing potential therapeutic effects on brain tumors. Considering the effects of DCA on tumor cellular metabolism, penetrating across the blood–brain barrier, as well as having potential antitumor activity on brain tumors, the purpose of this study is to investigate the antitumor activity of DCA on C6 glioma cells in vitro and in vivo. DCA inhibited C6 glioma cell proliferation, induced C6 cell apoptosis, and arrested C6 cells in S phase. DCA can inhibit the expression of heat shock proteins 70 (Hsp70) in a dose-dependent and time-dependent manner (P < 0.01). Our in vivo antitumor effect results indicated that DCA markedly inhibited the growth of C6 glioma tumors in both C6 brain tumor-bearing rats and C6 tumor-bearing nude mice (P < 0.01). DCA significantly induced the ROS production and decreased the mitochondrial membrane potential in tumor tissues. Our in vivo antitumor effect results also indicated that DCA has potential antiangiogenic effects. In conclusion, DCA may be a viable therapeutic agent in the treatment of gliomas.

show abstract

Antiangiogenic Activity of Sterically Stabilized Liposomes Containing Paclitaxel (SSL-PTX): In Vitro and In Vivo

Cited by 22 publications

References 29 publications

Multi-targeting NGR-modified liposomes recognizing glioma tumor cells and vasculogenic mimicry for improving anti-glioma therapy

Multi-targeting NGR-modified liposomes recognizing glioma tumor cells and vasculogenic mimicry for improving anti-glioma therapy

Liposomal paclitaxel formulations

Antitumor activity of dichloroacetate on C6 glioma cell: in vitro and in vivo evaluation

Contact Info

Product

Resources

About